| (USD) | Mar 2023 | Q/Q |
|---|---|---|
| Revenue | 19MM | -12% |
| Operating Income | -59.4MM | +39% |
| Operating Expenses | 78.3MM | +22% |
| Net Income | -60.8MM | - |
| R&D | 64.4MM | +25% |
| G&A | 13.9MM | +9% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
PASADENA, Calif., April 09, 2024--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of Bart Cornelissen to senior vice president and chief financial officer. Mr. Cornelissen has more than 20 years of experience in corporate financial planning, analysis and transaction support. Before joining Xencor, he was most recently vice president, corporate finance at
John Kuch, Senior Vice President & Chief Financial Officer of Xencor Inc (NASDAQ:XNCR), has sold 4,474 shares of the company on March 5, 2024, according to a recent SEC filing.
Bassil Dahiyat, President & CEO of Xencor Inc (NASDAQ:XNCR), sold 12,528 shares of the company on March 5, 2024, according to a recent SEC Filing.
Xencor ( NASDAQ:XNCR ) Full Year 2023 Results Key Financial Results Revenue: US$168.3m (up 2.3% from FY 2022). Net...
PASADENA, Calif., February 28, 2024--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company management will participate at multiple upcoming investor conferences:
Q4 2023 Xencor Inc Earnings Call
Xencor, Inc. (NASDAQ:XNCR) Q4 2023 Earnings Call Transcript February 28, 2024 Xencor, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and thank you for standing by. Welcome to Xencor’s Fourth Quarter and Year End 2023 Conference Call. […]
Xencor (XNCR) delivered earnings and revenue surprises of -186.11% and 68.25%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Encouraging Clinical Data Accompanies Financial Update
PASADENA, Calif., February 27, 2024--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a review of recent business and clinical highlights. The Company also presented encouraging early clinical data from its Phase 2 study of vudalimab monotherapy for patients with clinically defined